Company intelligence / Profile preview

NWRCM

Bethesda, Maryland, United Statesnwrcm.com ↗

Ownership: Private
Development stage: Other

Overview

Northwest Biotherapeutics is developing personalized immunotherapies using its proprietary DCVax platform. Its lead product, DCVax-L, is in Phase 3 trials for glioblastoma multiforme and has shown promising early results with some patients experiencing long-term survival and minimal side effects. Other programs include DCVax–Direct for inoperable solid tumors and DCVax-Prostate for late-stage prostate cancer. The company has received regulatory approvals related to manufacturing facilities but awaits pivotal trial data before commercialization.

Therapeutic areas: Oncology
Modalities: Cell therapyDendritic cell therapyAutologous cell therapy
Industry: Biotech

Partnerships

Cognate Bioservices (contract manufacturing organization)

Beyond the preview

Go deeper on NWRCM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWRCM.

Explore the full profile